A 52-year-old man develops jaundice, hepatomegaly, and elevated transaminases 6 weeks after starting an antituberculous regimen. Liver biopsy shows cholestasis with bile duct proliferation and minimal inflammation. Which feature best distinguishes this Type C (continuing) reaction from a Type A hepatotoxic reaction?

Explanation

## Type C (Continuing/Cumulative) Reactions vs Type A Hepatotoxicity ### Type C (Continuing) Reactions **Key Point:** Type C reactions develop insidiously after prolonged drug exposure and continue to progress even after the drug is stopped. They represent cumulative organ damage. - **Onset:** Delayed, after weeks to months of continuous exposure - **Dose-dependence:** Dose-independent (occurs at therapeutic doses) - **Progression:** Continues or worsens after drug withdrawal - **Mechanism:** Cumulative toxicity, often from reactive metabolites or chronic inflammation - **Examples:** - Antituberculous drug-induced cholestasis (isoniazid, rifampicin) - Methotrexate-induced cirrhosis - Amiodarone-induced pulmonary fibrosis - Tetracycline-induced fatty liver progressing to cirrhosis - **Reversibility:** Slow or incomplete; may result in permanent organ damage ### Type A (Augmented) Hepatotoxicity **Key Point:** Type A hepatotoxicity is dose-dependent and reversible upon dose reduction or discontinuation. - **Onset:** Related to dose and duration - **Dose-dependence:** YES — occurs at higher doses or with dose escalation - **Progression:** Stops immediately upon drug withdrawal - **Mechanism:** Exaggeration of known pharmacological action or direct hepatocellular injury - **Examples:** - Acetaminophen overdose (dose-dependent hepatonecrosis) - Statins at high doses - **Reversibility:** Rapid and complete upon discontinuation ### Clinical Scenario Analysis The patient in the vignette presents with: - **6-week delay** (not immediate) → suggests Type C - **Cholestasis with bile duct proliferation** (chronic pattern) → suggests Type C - **Continuing on antituberculous drugs** (cumulative exposure) → Type C signature - **Minimal inflammation** (not acute hepatitis) → Type C pattern This is **antituberculous drug-induced cholestasis**, a classic Type C reaction (most commonly from isoniazid or rifampicin). ### Comparison Table | Feature | Type A (Augmented) | Type C (Continuing) | |---------|-------------------|---------------------| | **Onset** | Dose-related, variable | Delayed (weeks–months) | | **Dose-dependence** | Yes, predictable | No, occurs at therapeutic doses | | **Progression after withdrawal** | Stops immediately | Continues or worsens | | **Reversibility** | Rapid and complete | Slow, often incomplete | | **Mechanism** | Direct toxicity or exaggerated action | Cumulative metabolite injury | | **Histology** | Acute hepatocellular necrosis | Cholestasis, fibrosis, cirrhosis | | **Examples** | Acetaminophen OD, statin toxicity | Antituberculous drugs, methotrexate | **High-Yield:** The **delayed onset after prolonged exposure and dose-independent nature** are the hallmarks of Type C reactions. They differ from Type A by continuing to progress after drug withdrawal. **Mnemonic:** **C = Continuing, Cumulative, Chronic** — Type C reactions develop slowly, accumulate over time, and persist after drug withdrawal. **Clinical Pearl:** Type C reactions are particularly important in antituberculous therapy monitoring. Baseline and periodic liver function tests are essential to detect early cholestasis before irreversible cirrhosis develops.